AZN Stock Recent News

AstraZeneca PLC (NASDAQ:AZN ) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Scaltrisi - Head of Traditional Medicine Leora Horn - Global Clinical Strategy Head for Lung Conference Call Participants Tony Ryan - Macquarie Emily Field - Barclays Christopher Uhde – SEB Simon Baker - Redburn Sam Fazeli - Bloomberg Intelligence Alana Lelo - Guggenheim Richard Parks - BNP Paribas Exane Andrew Berens - Leerink Partners Etzer Darout - BMO Capital Markets Gonzalo Artiach - Danske Bank Mattias Haggblom - Handelsbanken James Gordon - JPMorgan Luisa Hector - Berenberg R

Investors like to think of themselves as rational and unattached. Still, the movement of stock prices shows that this isn't always true — and the existence of technical signals like oversold or undersold confirms that fact.

CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.

TAMPA, Fla.--(BUSINESS WIRE)--Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies. Under this collaboration, AstraZeneca will have priority access to Moffitt's leading clinical environment and forge strong connections between physician-scientists to accelerate the investigation of novel cell therapies. Advances in cel.

AstraZeneca's Dato-DXd showed disappointing overall survival data in the TROPION-Lung01 phase 3 trial. Dato-DXd's progression-free survival benefit, especially in biomarker-positive patients, and the totality of the data, support its potential approval despite underwhelming overall survival results. AstraZeneca has many additional shots on goal with Dato-DXd across first and second line+ lung cancer and breast cancer.

A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not significantly improve patients' overall survival rates.

Shares in AstraZeneca PLC (LSE:AZN) were the biggest drag on the FTSE 100 on Tuesday, falling over 4.5% on the back of some disappointing results from a trial of a lung cancer drug. Late-stage trial results of the TROPION-Lung01 showed that the overall survival rate from the new drug “did not reach statistical significance,” the company said.

London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.

Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.

AstraZeneca PLC (LSE:AZN) shares fell 3.5% after it confirmed that five current and former employees in China are being held by police for questioning. The individuals, all Chinese nationals, worked in the company's oncology division marketing cancer treatments, with the police detentions made in the city of Shenzhen earlier this summer.